• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于吩噻嗪的苯甲羟肟酸的合成与生物研究作为选择性组蛋白去乙酰化酶 6 抑制剂。

Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.

机构信息

Department of Pharmacy-Center for Drug Research , Ludwig-Maximilians University Munich , Butenandtstr. 5-13 , 81377 Munich , Germany.

Institute of Pharmaceutical Sciences , University of Freiburg , Albertstraße 25 , 79104 Freiburg , Germany.

出版信息

J Med Chem. 2019 Feb 14;62(3):1138-1166. doi: 10.1021/acs.jmedchem.8b01090. Epub 2019 Feb 1.

DOI:10.1021/acs.jmedchem.8b01090
PMID:30645113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6519732/
Abstract

The phenothiazine system was identified as a favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors. Here, we report the preparation and systematic variation of phenothiazines and their analogues containing a benzhydroxamic acid moiety as the zinc-binding group. We evaluated their ability to selectively inhibit HDAC6 by a recombinant HDAC enzyme assay, by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines. Structure-activity relationship studies revealed that incorporation of a nitrogen atom into the phenothiazine framework results in increased potency and selectivity for HDAC6 (more than 500-fold selectivity relative to the inhibition of HDAC1, HDAC4, and HDAC8), as rationalized by molecular modeling and docking studies. The binding mode was confirmed by co-crystallization of the potent azaphenothiazine inhibitor with catalytic domain 2 from Danio rerio HDAC6.

摘要

苯并噻嗪系统被确定为具有高效和选择性的组蛋白去乙酰化酶 6(HDAC6)抑制剂的理想盖帽基团。在这里,我们报告了苯并噻嗪及其类似物的制备和系统变化,这些化合物含有苯甲羟肟酸部分作为锌结合基团。我们通过重组 HDAC 酶测定法评估了它们通过选择性抑制 HDAC6 的能力,通过 Western blot(微管蛋白与组蛋白乙酰化)测定细胞中蛋白质乙酰化水平,以及通过评估它们对各种癌细胞系的影响来评估。构效关系研究表明,将氮原子引入苯并噻嗪骨架中可显著提高对 HDAC6 的选择性和效力(与抑制 HDAC1、HDAC4 和 HDAC8 相比,选择性超过 500 倍),这可以通过分子建模和对接研究得到合理化。通过与斑马鱼 HDAC6 的催化结构域 2 共结晶,证实了该有效氮杂苯并噻嗪抑制剂的结合模式。

相似文献

1
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.基于吩噻嗪的苯甲羟肟酸的合成与生物研究作为选择性组蛋白去乙酰化酶 6 抑制剂。
J Med Chem. 2019 Feb 14;62(3):1138-1166. doi: 10.1021/acs.jmedchem.8b01090. Epub 2019 Feb 1.
2
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.组蛋白去乙酰化酶抑制剂的结构要求:C4修饰的SAHA类似物具有HDAC6/HDAC8双重选择性。
Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.
3
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.恶唑异羟肟酸酯作为高选择性组蛋白去乙酰化酶6(HDAC6)抑制剂的合成及生物学研究
J Med Chem. 2016 Feb 25;59(4):1545-55. doi: 10.1021/acs.jmedchem.5b01493. Epub 2015 Dec 22.
4
Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.具有咪唑酮哌嗪帽的异构体选择性 HDAC1/6/8 抑制剂,包含立体化学多样性。
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748). doi: 10.1098/rstb.2017.0364.
5
Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.四氢-β-咔啉衍生物的设计与生物评价:作为高效组蛋白去乙酰化酶 6(HDAC6)抑制剂。
Eur J Med Chem. 2018 May 25;152:329-357. doi: 10.1016/j.ejmech.2018.04.046. Epub 2018 Apr 26.
6
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.HDAC6 选择性羟肟酸抑制剂的不寻常锌结合模式。
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13459-13464. doi: 10.1073/pnas.1718823114. Epub 2017 Dec 4.
7
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.噻唑基-羟肟酸衍生物作为选择性组蛋白去乙酰化酶 6 抑制剂的构效关系研究。
Bioorg Med Chem. 2019 Aug 1;27(15):3408-3420. doi: 10.1016/j.bmc.2019.06.036. Epub 2019 Jun 20.
8
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.PTG-0861:一种新型组蛋白去乙酰化酶 6 选择性抑制剂,可作为急性髓系白血病的治疗策略。
Eur J Med Chem. 2020 Sep 1;201:112411. doi: 10.1016/j.ejmech.2020.112411. Epub 2020 Jun 6.
9
Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.基于新型 3-羟基异恶唑锌结合基团的组蛋白去乙酰化酶 6 抑制剂。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2080-2086. doi: 10.1080/14756366.2021.1981306.
10
Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.羧酸衍生物对人组蛋白去乙酰化酶 6 具有潜在的选择性:基于结构的虚拟筛选、分子对接和动力学模拟研究。
Comput Biol Chem. 2018 Aug;75:131-142. doi: 10.1016/j.compbiolchem.2018.05.004. Epub 2018 May 16.

引用本文的文献

1
Discovery of Novel Imidazothiazole-Based Hydroxamic Acid Derivatives as Potent Indoleamine 2,3-Dioxygenase 1 and Histone Deacetylase 6 Dual Inhibitors.发现新型基于咪唑并噻唑的异羟肟酸衍生物作为强效吲哚胺2,3-双加氧酶1和组蛋白去乙酰化酶6双重抑制剂
Molecules. 2025 Jun 7;30(12):2508. doi: 10.3390/molecules30122508.
2
Serendipitous and Systematic Chemoproteomic Discovery of MBLAC2, HINT1, and NME1-4 Inhibitors from Histone Deacetylase-Targeting Pharmacophores.从靶向组蛋白去乙酰化酶的药效团中偶然发现并系统化学蛋白质组学鉴定出MBLAC2、HINT1和NME1-4抑制剂
ACS Chem Biol. 2025 Jun 20;20(6):1247-1257. doi: 10.1021/acschembio.5c00108. Epub 2025 May 8.
3
Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies.增强组蛋白去乙酰化酶抑制剂筛选:解决对接研究中的锌参数化和配体质子化问题。
Int J Mol Sci. 2025 Jan 20;26(2):850. doi: 10.3390/ijms26020850.
4
Design, synthesis, biological and evaluation of 3‑carboxy‑coumarin sulfonamides as potential antiproliferative agents targeting HDAC6.作为靶向HDAC6的潜在抗增殖剂的3-羧基香豆素磺酰胺的设计、合成、生物学研究及评价
Biomed Rep. 2024 Oct 30;22(1):6. doi: 10.3892/br.2024.1884. eCollection 2025 Jan.
5
Synthesis and biological evaluation of -phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases.含吩噻嗪的 - 苯基苯基羟肟酸的合成及生物评价,对 IIa 类组蛋白去乙酰化酶具有改善的选择性。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2406025. doi: 10.1080/14756366.2024.2406025. Epub 2024 Sep 24.
6
Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.阿尔茨海默病的最新进展:机制、临床试验和新药研发策略。
Signal Transduct Target Ther. 2024 Aug 23;9(1):211. doi: 10.1038/s41392-024-01911-3.
7
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.催化和抑制 IIb 类组蛋白去乙酰化酶中的化学多功能性。
Acc Chem Res. 2024 Apr 16;57(8):1135-1148. doi: 10.1021/acs.accounts.3c00801. Epub 2024 Mar 26.
8
Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor.利用优化的AlphaFold模型进行基于结构的比较虚拟筛选,鉴定出选择性HDAC11抑制剂。
Int J Mol Sci. 2024 Jan 22;25(2):1358. doi: 10.3390/ijms25021358.
9
Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation.开发首创的 Sirt2/HDAC6 双重抑制剂作为双重抑制微管去乙酰化的分子工具。
J Med Chem. 2023 Nov 9;66(21):14787-14814. doi: 10.1021/acs.jmedchem.3c01385. Epub 2023 Oct 30.
10
Divergent access to 5,6,7-perifused cycles.对5、6、7周外周灌注周期的不同获取方式。
Nat Commun. 2023 Aug 24;14(1):5148. doi: 10.1038/s41467-023-40801-0.

本文引用的文献

1
Histone deacetylase 6 in cancer.组蛋白去乙酰化酶 6 在癌症中的作用。
J Hematol Oncol. 2018 Sep 3;11(1):111. doi: 10.1186/s13045-018-0654-9.
2
Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.抑制细胞周期蛋白依赖性激酶 5:提高索拉非尼治疗肝细胞癌疗效的策略。
Hepatology. 2019 Jan;69(1):376-393. doi: 10.1002/hep.30190. Epub 2018 Dec 22.
3
and activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.以及一种新型HDAC6小分子抑制剂在套细胞淋巴瘤中的活性。
Haematologica. 2018 Nov;103(11):e537-e540. doi: 10.3324/haematol.2018.189241. Epub 2018 Jun 7.
4
The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.新型组蛋白去乙酰化酶 6 抑制剂 MPT0G211 可改善阿尔茨海默病模型中的 Tau 磷酸化和认知缺陷。
Cell Death Dis. 2018 May 29;9(6):655. doi: 10.1038/s41419-018-0688-5.
5
Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]pyridine-Capped Selective HDAC6 Inhibitors.咪唑并[1,2- a]吡啶封端的选择性 HDAC6 抑制剂的多组分合成及结合模式。
Org Lett. 2018 Jun 1;20(11):3255-3258. doi: 10.1021/acs.orglett.8b01118. Epub 2018 May 23.
6
Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.具有咪唑酮哌嗪帽的异构体选择性 HDAC1/6/8 抑制剂,包含立体化学多样性。
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748). doi: 10.1098/rstb.2017.0364.
7
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.Marbostat-100 定义了一类新型强效、选择性的抗炎和抗风湿组蛋白去乙酰化酶 6 抑制剂。
J Med Chem. 2018 Apr 26;61(8):3454-3477. doi: 10.1021/acs.jmedchem.7b01593. Epub 2018 Apr 6.
8
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.组蛋白去乙酰化酶(HDAC)抑制剂ACY241 增强了抗原特异性中枢记忆细胞毒性 T 淋巴细胞对多发性骨髓瘤和实体瘤的抗肿瘤活性。
Leukemia. 2018 Sep;32(9):1932-1947. doi: 10.1038/s41375-018-0062-8. Epub 2018 Feb 22.
9
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.HDAC6 选择性羟肟酸抑制剂的不寻常锌结合模式。
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13459-13464. doi: 10.1073/pnas.1718823114. Epub 2017 Dec 4.
10
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.新型组蛋白去乙酰化酶6(HDAC6)抑制剂ACY-241与抗程序性死亡配体1(PD-L1)抗体联合使用可增强多发性骨髓瘤的抗肿瘤免疫力和细胞毒性。
Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6.